BioTuesdays

Tag - NRSN

NeuroSense Therapeutics

Maxim starts NeuroSense at buy; PT $7

Maxim Group initiated coverage of NeuroSense Therapeutics (NASDAQ:NRSN) with a “buy” rating and price target of $7. The stock closed at $2.53 on Jan. 6. NeuroSense is a clinical-stage company developing therapies for...

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.